Parmax Pharma Shows Strong Growth with 212.61% Increase in Net Sales

Parmax Pharma, a microcap pharmaceutical company, has recently announced its financial results for the quarter ending September 2024. The company has shown a positive performance in the second quarter of the fiscal year 2024-2025, with its score improving from 4 to 11 in the last 3 months.

One of the key factors contributing to this growth is the company's net sales, which have increased by 212.61% year on year, reaching Rs 17.10 crore in the first half of the fiscal year. This is a significant improvement compared to the same period last year, where the company's net sales were only Rs 11.06 crore. This indicates a strong and positive sales trend for Parmax Pharma.

In fact, the company's net sales for the first half of the fiscal year have already surpassed the sales of the entire previous year. This is a promising sign for Parmax Pharma and shows the company's potential for continued growth in the future.

Based on these financial results, MarketsMOJO has given a 'Sell' call for Parmax Pharma's stock. However, it is important to note that this is not a recommendation from experts or investors, but rather a neutral assessment based on the company's financial performance. With its positive sales trend and strong financials, Parmax Pharma is definitely a company to watch in the pharmaceutical industry.